Treatment of chronic myeloid leukemia in the imatinib era: Perspective from a developing country

Cancer

Volumn 109, Issue 6, 2007, Pages 1138-1145

  Aziz, Zeba ^a   Iqbal, Javaid ^a   Akram, Mohammad ^a   Saeed, Sarah ^a  

^a JINNAH HOSPITAL   (Pakistan)

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Developing country; Imatinib mesylate; Toxicities

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; INTERFERON;

ADOLESCENT; ADULT; AGED; ANEMIA; BLAST CELL; BLOOD CELL COUNT; BLOOD EXAMINATION; BONE MARROW; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEVELOPING COUNTRY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CYTOGENETIC ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PAKISTAN; PIPERAZINES; PYRIMIDINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33947245976     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22498     Document Type: Review

References (45)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-1340.
3. Lee SJ. Chronic myeloid leukemia. Br J Hematol. 2000;111: 993-1009.
4. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16 year period. Br J Hematol. 1997;96:111-116.
5. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
6. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol. 1988;25:20-34.
7. Wang JYJ. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev. 1993;3:35-43.
8. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
9. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myeloid leukemia. Exp Hematol. 2001;29: 543-556.
10. Savage DG, Goldman JM. Chronic myelogenous leukemia. In: Armitage JO, Antman KH, eds. High Dose Therapy: Pharmacology, Hematopoetins, Stem Cells. Baltimore, Md: Williams & Wilkins; 1999:705-731.
11. Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer. 1982;50:1683-1686.
12. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose-interferon-alpha 2bfor chronic myeloid leukemia. Blood. 1998;91:2713-2721.
13. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulphan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 2001;94:1517-1536.
14. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myeloid leukemia. Blood. 1994;84:4064-4077.
15. A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065-1069.
16. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
17. [No authors listed.] Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997;89:1616-1620.
18. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon α versus interferon α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527-1535.
19. Kantarjian HM, O'Brien S, Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
20. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon alpha for chronic myeloid leukemia. Semin Hematol. 2003; 40:22-33.
21. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
22. Kantarjian HM, O'Brien S, Cortes J, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long term prognosis. Cancer. 2003;97:1033-1041.
23. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214-220.
24. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
25. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
26. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomized multicentre trial of interferon-alpha 1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. Lancet. 1995;345:1392-1397.
27. Ohnishi K, Ohno R, Tomonago M, et al. A randomized trial comparing interferon alpha with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
28. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337: 223-229.
29. Goldman JM, Drucker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;98:2039-2042.
30. Italian Cooperative Study Group on Chronic Myeloid Leukemia andltalian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999;17:1858-1868.
31. Simonsson B, Oberg G, Bjoreman M, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long term follow-up. Acta Haematol. 2005; 113:155-162.
32. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
33. Kantarjian HM, Cortes J, O'Brien S, et al. Long term survival benefit and improved complete cytogenetic and molecular response rate with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979-1988.
34. Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood. 2004;103:2284-2290.
35. Talpaz M, Silver RT, Drucker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses inpatients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
36. Drucker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
37. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344:1084-1086.
38. Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113:11-23.
39. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
40. Funke VAM, Medeiro CR, Lima DH, et al. Therapy of chronic myeloid leukemia with Imatinib mesylate in Brazil: a study of 98 cases. Rev Bras Hematol Hemoter. 2005;27:159-165.
41. Farlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2001.
42. Kantarjian, HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98:2636-2642.
43. Kantarjian, HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer. 2004;103:2099-2108.
44. Hahn EA, Glendenning GA, Sorenson MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alpha plus low-dose cytarabine: results from the IRIS study. J Clin Oncol. 2003;21:2138-2146.
45. Hughes TP, Branford S, Reynolds J, et al. Frequencies of major molecular responses to imatinib or interferon alfa plus low-dose cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1421-1432.